Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Account Payables
Amounts the company owes suppliers for goods and services received.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 206.7% from a year ago
Account payables stood at $6.56M at the end of Q1 FY2026, up 206.7% from a year earlier and up 56.6% from the prior quarter. Over 3 fiscal years it compounded at +42.4% a year.
Context
- Account payables amounted to 1.3% of total assets at the end of Q1 FY2026, up 0.6 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +206.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 4.19M USD
- Year-over-year change
- +114.4%
- 3-year CAGR
- +42.4%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.19M | +114.4% |
| FY2024 | 2024-12-31 | 1.95M | -21.9% |
| FY2023 | 2023-12-31 | 2.5M | +72.6% |
| FY2022 | 2022-12-31 | 1.45M | — |
Account Payables vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's Mar 2026 account payables of $6.56M is the 5th highest of the 10 companies compared; the peer median is $5.06M.
- Its year-over-year change of +206.7% is the 3rd highest of 10, against a peer median of -13.8%.
- Account payables amounts to 1.3% of total assets for RAPP, versus a peer median of 1.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $78.97M | -13.8% | +19.3% | 10.4% | |
| Sep 2026 | $16.33M | -24.9% | -5.1% | 0.9% | |
| Sep 2026 | $15.02M | -51.3% | +18.8% | 1.1% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $7.12M | +1021.1% | +138.9% | 1.8% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $6.56M | +206.7% | +42.4% | 1.3% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $5.06M | +380.7% | -22.1% | 3.3% |
| Mar 2026 | $3.85M | +111.4% | -29.7% | 10.7% | |
| Mar 2026 | $3.37M | +143.4% | +5.4% | 1.2% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $1.5M | -59.0% | +33.2% | 0.6% |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | $5.06M | -13.8% | +12.1% | 1.2% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.